Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fluticasone propionate + formoterol fumarate (Aché Laboratórios Farmacêuticos)
- Development stage
- Phase 3
- Lead developer
- GSK
- Modality
- Small Molecules
- Administration
- Inhalation
01
Overview
Lugano is a fixed-dose combination (FDC) inhalation therapy developed by Ache Laboratorios Farmaceuticos S.A. for the treatment of chronic obstructive pulmonary disease (COPD) and asthma. It combines fluticasone propionate, a synthetic trifluorinated corticosteroid with potent anti-inflammatory activity, and formoterol fumarate, a long-acting selective beta-2 adrenergic receptor agonist (LABA) that induces bronchodilation. The product is administered via a dry powder inhaler using capsules containing the active ingredients. In clinical trials, such as the Phase III study NCT01393145, the combination demonstrated efficacy and safety comparable to other established ICS/LABA combinations like salmeterol/fluticasone in improving lung function and managing symptoms in patients with moderate-to-severe COPD. It is primarily marketed in Brazil.
- Brand names
- Lugano
- Other names
- Formoterol/Fluticasone Ache
02
Targets
ADRB2 (β2)PLA2G4A (Cytosolic phospholipase A2 alpha)GR (Glucocorticoid receptor)MR (Mineralocorticoid receptor)PR (Progesterone receptor)
Beyond the preview
Go deeper on fluticasone propionate + formoterol fumarate (Aché Laboratórios Farmacêuticos).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fluticasone propionate + formoterol fumarate (Aché Laboratórios Farmacêuticos).